• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Auckland's major hospital reports outbreak of (ESBL) superbug

Shiloh

Editor, Senior Moderator
Source: http://news.xinhuanet.com/english/2009-10/24/content_12313914.htm

Auckland's major hospital reports outbreak of superbug
www.chinaview.cn 2009-10-24 12:13:06

WELLINGTON, Oct. 24 (Xinhua) -- A superbug outbreak at a major hospital in Auckland, New Zealand's biggest city, has become so serious that officials are considering splitting wards in an effort to control it, local media reported Saturday.

Up to one in five patients at Auckland's North Shore Hospital are contracting extended spectrum beta lactamase (ESBL), about 70 percent of them while in hospital, Radio New Zealand reported on Saturday.


Patients at the Hospital are divided between three rooms, one for those that test positive for the superbug, another for those waiting for results and a third for those that have been cleared.

At the peak of the outbreak in April, 245 patients in North Shore Hospital and Waitakere Hospital caught ESBL -- producing bacteria -- is resistant to a range of antibiotic drugs.

Five elderly patients who had the superbug and also other illnesses, died in the nine months to April.

Improved hygiene measures reduced the number of infections to 162 in August.

North Shore hospital Chief Medical Officer Johan Rosman said ESBL was different from other superbugs because it stayed in people 's bodies for a long time, even after they had been treated with antibiotics.

He said it was important to wash hands and use hand gels often, to optimize hygiene.

In the meantime the hospital is to ask Waitemata District Health Board to consider splitting medical and surgical wards to ensure patients with the bug have separate staff from those that don't.

The superbug is usually carried in the bowel but if it crosses into the bloodstream it can be fatal.
 
Re: Auckland's major hospital reports outbreak of (ESBL) superbug

The Ministry of Health says a superbug affecting two hospitals in Auckland has the potential to affect hospitals nationwide.

At the peak of the outbreak in April, 245 patients in North Shore Hospital and Waitakere Hospital caught extended spectrum beta lactamase (ESBL).

Five elderly patients who had the superbug, but also had other illnesses, died in the nine months to April.

Improved hygiene measures reduced the number of infections to 162 in August.

The ministry's chief advisor on population health, Dr Greg Simmons, says hospitals are taking extra precautions, particularly with patients who have been in hospitals overseas.

People who have recently been in a hospital overseas will have swabs taken, and if ESBL is present, measures will be taken to ensure it does not spread to other patients.

Waitemata District Health Board may have to consider splitting hospital wards in an effort to control ESBL.

Patients at North Shore Hospital are divided between three rooms, one for those that test positive for the superbug, another for those waiting for results and a third for those that have been cleared.

But staff shortages mean some nurses work in more than one room during their shift.

Now the hospital is to ask the district health board to consider splitting medical and surgical wards to ensure patients with the bug have separate staff from those that don't.The superbug is usually carried in the bowel, but can be fatal if it crosses into the bloodstream.

http://www.radionz.co.nz/news/stories/2009/10/24/1245ce5b2f32
 
Re: Auckland's major hospital reports outbreak of (ESBL) superbug

1: Clin Microbiol Rev. 2001 Oct;14(4):933-51, table of contents. Links

Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat.

Bradford PA.
Wyeth-Ayerst Research, Pearl River, New York 10965, USA. bradfop@war.wyeth.com

Beta-lactamases continue to be the leading cause of resistance to beta-lactam antibiotics among gram-negative bacteria. In recent years there has been an increased incidence and prevalence of extended-spectrum beta-lactamases (ESBLs), enzymes that hydrolyze and cause resistance to oxyimino-cephalosporins and aztreonam. The majority of ESBLs are derived from the widespread broad-spectrum beta-lactamases TEM-1 and SHV-1.

There are also new families of ESBLs, including the CTX-M and OXA-type enzymes as well as novel, unrelated beta-lactamases. Several different methods for the detection of ESBLs in clinical isolates have been suggested.

While each of the tests has merit, none of the tests is able to detect all of the ESBLs encountered. ESBLs have become widespread throughout the world and are now found in a significant percentage of Escherichia coli and Klebsiella pneumoniae strains in certain countries. They have also been found in other Enterobacteriaceae strains and Pseudomonas aeruginosa.

Strains expressing these beta-lactamases will present a host of therapeutic challenges as we head into the 21st century.

PMID: 11585791 [PubMed - indexed for MEDLINE

http://www.ncbi.nlm.nih.gov/pubmed/11585791
 
Back
Top